Last reviewed · How we verify
FSR Peptide 20μM — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
FSR Peptide 20μM (FSR Peptide 20μM) — Xequel Bio, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FSR Peptide 20μM TARGET | FSR Peptide 20μM | Xequel Bio, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FSR Peptide 20μM CI watch — RSS
- FSR Peptide 20μM CI watch — Atom
- FSR Peptide 20μM CI watch — JSON
- FSR Peptide 20μM alone — RSS
Cite this brief
Drug Landscape (2026). FSR Peptide 20μM — Competitive Intelligence Brief. https://druglandscape.com/ci/fsr-peptide-20-m. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab